Patents by Inventor Alan Peter Lewis

Alan Peter Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11098312
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 24, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Robyn Alexandra Emmins, Gary Brian Finka, Michael Hoare, Alan Peter Lewis, William John Kenneth Lewis, Adam Daniel McInally, Mark Uden, Ioannis Voulgaris
  • Patent number: 11078287
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Tejinder Kaur Bhinder, Chong Ding, Xu Feng, Wenqing Jiang, Alan Peter Lewis, Yingli Ma, Guhan Nagappan, Radha Shah Parmar, Yangsheng Qiu, Liuqing Yang, Qing Zhang, Yanjiao Zhou
  • Publication number: 20210115128
    Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Application
    Filed: May 21, 2019
    Publication date: April 22, 2021
    Inventors: Chika AKINSEYE, Tejinder BHINDER, Li CUI, Steven GRANT, Laura HOOK, Alan Peter LEWIS, Martin Anibal ORECCHIA
  • Publication number: 20210017293
    Abstract: The present invention relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g. fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains e.g. human immunoglobulin (antibody) single variable domains, and also single variable domains derived from non-human sources such as a llama or camel, e.g. a VHH including a Nanobody™ (described in e.g. WO 94/04678 and WO 95/04079 inter alia). The invention further relates to uses, formulations, compositions comprising such modified C terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these molecules.
    Type: Application
    Filed: September 8, 2020
    Publication date: January 21, 2021
    Inventors: Claire Ashman, Mary Birchler, Rudolf M.T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • Publication number: 20200339663
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 29, 2020
    Inventors: Valeriu DAMIAN, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 10808040
    Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Mary Birchler, Rudolf M. T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • Publication number: 20200197529
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 25, 2020
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Publication number: 20200165345
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Application
    Filed: November 15, 2016
    Publication date: May 28, 2020
    Inventors: Tejinder Kaur BHINDER, Chong DING, Xu FENG, Wenqing JIANG, Alan Peter LEWIS, Yingli MA, Guhan NAGAPPAN, Radha Shah PARMAR, Yangsheng QIU, Liuqing YANG, Qing ZHANG, Yanjiao ZHOU
  • Publication number: 20190382482
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 19, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • Publication number: 20190276535
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 12, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew WEBB
  • Patent number: 10344088
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Publication number: 20190177734
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Application
    Filed: May 4, 2017
    Publication date: June 13, 2019
    Inventors: Robyn Alexandra EMMINS, Gary Brian FINKA, Michael HOARE, Alan Peter LEWIS, William John Kenneth LEWIS, Adam Daniel McINALLY, Mark UDEN, Ioannis VOULGARIS
  • Patent number: 10280221
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 7, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Patent number: 10221234
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Tejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Publication number: 20180222964
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Inventors: Valeriu DAMIAN, Austin Keith DOYLE, Laura Maria HALO, Emma R. HARDING, Xuan HONG, Alan Peter LEWIS, Mark UDEN
  • Publication number: 20180147293
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: December 1, 2017
    Publication date: May 31, 2018
    Inventors: PAUL ALGATE, STEPHANIE JANE CLEGG, JENNIFER L. CRAIGEN, PAUL ANDREW HAMBLIN, ALAN PETER LEWIS, PATRICK MAYES, RADHA SHAH PARMAR, TREVOR ANTHONY KENNETH WATTAM
  • Patent number: 9914781
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 13, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Tejinder Kaur Bhinder, Chong Ding, Xu Feng, Wenqing Jiang, Alan Peter Lewis, Yingli Ma, Guhan Nagappan, Radha Shah Parmar, Yangsheng Qiu, Liuqing Yang, Qing Zhang, Yanjiao Zhou
  • Publication number: 20170029494
    Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Claire ASHMAN, Ian Richard Catchpole, Zoe Hughes-Thomas, Alan Peter Lewis, Michael Steward
  • Patent number: 9499612
    Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: November 22, 2016
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Ian Richard Catchpole, Zoe Hughes-Thomas, Alan Peter Lewis, Michael Steward
  • Publication number: 20160333086
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Application
    Filed: August 5, 2016
    Publication date: November 17, 2016
    Inventors: Tejinder Kaur BHINDER, Susannah Karen FORD, Volker GERMASCHEWSKI, Alan Peter LEWIS, Mark Brian PEPYS